AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 62 min read$ABBV

HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.

HSBC analyst Rajesh Kumar raised AbbVie's price target to $315 from $300, citing growth potential from drugs Skyrizi and Rinvoq. Kumar expects earnings growth to accelerate, potentially rerating shares. AbbVie trades at 16x forward earnings, with a 2.6% dividend yield. The company's recent acquisition and strong sales of new drugs support long-term growth prospects.

Original reporting
finance.yahoo.com
Published Oct 6, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The upgrade could attract new buying interest and support the stock price, especially if label expansions materialize.

02

Market read

Analyst upgrade may prompt short-term buying pressure in ABBV and influence sentiment in the pharma sector.

03

What to watch

Potential headwinds from competition and the need for sustained label expansion to justify a rerating.

Relevance 7/10Novelty 7/10Timing: immediate today

Background

HSBC analyst Rajesh Kumar issued a bullish price target upgrade for AbbVie, focusing on its immunology drugs Skyrizi and Rinvoq and recent acquisition of Apogee Therapeutics.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

HSBC analyst raised price target to $315 and maintained buy rating, citing label expansion and pipeline growth.

Expected impact

likely upward pressure as investors price in higher earnings growth and possible rerating.

Evidence & confidence

The new target reflects fresh bullish thesis on Skyrizi and Rinvoq, which could drive buying interest.

Market effects

Sector

Positive for the broader pharma sector as label expansions may set a precedent for peers.

Regional

U.S. market may see modest gains in healthcare stocks.

Global

Limited to investors tracking large-cap pharma equities.

Counterpoint

What could challenge this read

The price target may be overly optimistic given valuation already at 16x forward earnings.

Key entities

  • company
    AbbVie

    Pharmaceutical company receiving the upgraded price target.

  • financial_institution
    HSBC

    Analyst firm providing the new target.

Read at source← All news

Related articles

OCT 6
$ABBVMed

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

AbbVie (ABBV) shares rose 0.3% to $266.63 on Oct. 6 after a late-stage trial showed its blood-cancer treatment, epcoritamab plus R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone in diffuse large B-cell lymphoma. The trial's hazard ratio was 0.49, with a p-value below 0.0001, and safety was consistent with known profiles.

finance.yahoo.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

theglobeandmail.com2 min
OCT 6
$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min
OCT 6
$ABBVMed

AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.

oncodaily.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3

AbbVie and Genmab's Epkinly reduced disease progression or death risk by 51% in a Phase 3 trial for frontline DLBCL treatment, exceeding expectations. The study enrolled 900 patients and showed significant improvement over R-CHOP alone. Genmab's shares rose 11% following the data release. Epkinly is already approved for later-stage treatment and could compete with Roche's Polivy and Incyte's Monjuvi if approved for first-line use.

biospace.com2 min